A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
מצבים רפואיים
Bronchiectasis
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, United Kingdom
Contact: Principal Investigator (Charles Haworth)Tayside Medical Science Centre, Ninewells Hospital & Medical School, Dundee, United Kingdom
Contact: Principal Investigator (James D. Chalmers)NHS Lothian, Edinburgh, United Kingdom
Contact: Principal Investigator (Adam Hill)Glasgow Royal Infirmary, Glasgow, United Kingdom
Contact: Principal Investigator (Lyn Corry)The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds, United Kingdom
Royal Bromptom Hospital (NHS Guy's and Thomas'), London, United Kingdom
Contact: Principal Investigator (Michael Loebinger)Manchester University NHS Foundation Trust, Manchester, United Kingdom
Contact: Principal Investigator (Robert Lord)Medicines Evaluation Unit (MEU), Manchester, United Kingdom
Contact: Principal Investigator (Dave Singh)University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Contact: Principal Investigator (Mary Carroll)
מובילי המחקר
James D. Chalmers
Principal Investigator
School of Medicine, University of Dundee, UK